H.C. Wainwright initiated coverage of Ionis Pharmaceuticals (IONS) with a Buy rating and $45 price target Ionis is a commercial-stage biotech company focused on RNA-targeted therapeutics for a range of diseases, the analyst tells investors in a research note. The firm says the company has a pipeline of successful antisense oligonucleotide therapies. It sees an opportunity to own Ionis ahead of 2025 catalysts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals management to meet with Oppenheimer
- Promising Potential of Ionis Pharmaceuticals’ Pelacarsen Drives Buy Rating Amidst Phase 3 HORIZON Trial Optimism
- Ionis Pharmaceuticals initiated with a Neutral at Redburn Atlantic
- Ionis Pharmaceuticals enters exclusive olezarsen license agreement with Sobi
- Ionis Pharmaceuticals price target lowered to $45 from $47 at JPMorgan